$XOMA News

XOMA Royalty Corporation (NASDAQ:XOMA) Checks Nearly Every Box in Louis Navellier’s Eight-Rule Growth Stock Screen

CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates

HC Wainwright & Co. Downgrades XOMA Royalty to Neutral, Announces $39 Price Target

XOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator

XOMA Royalty shares are trading higher after the company announced that it will be acquired by Ligand Pharmaceuticals for $39.00 per share in cash plus one contingent value right.

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

XOMA Royalty Corporation (NASDAQ:XOMA) Passes Key Growth and Momentum Filters

XOMA Royalty Corporation (NASDAQ:XOMA) Passes Strict "Little Book" Growth Stock Screen

We Believe XOMA Royalty's (NASDAQ:XOMA) Earnings Are A Poor Guide For Its Profitability

HC Wainwright & Co. Reiterates Buy on XOMA Royalty, Maintains $97 Price Target

XOMA Royalty Q4 Earnings Call Highlights

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Corporation (NASDAQ:XOMA) Beats Q4 2025 Earnings Estimates, Stock Rises

XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements

XOMA Royalty Jumps After Q4 Double Beat, Signals Pipeline Catalysts Ahead

XOMA Q4 EPS $0.26 Beats $(0.15) Estimate, Sales $13.757M Beat $11.049M Estimate